SECsense Logo

Akebia Therapeutics, Inc. 8-K Report: Key Developments on January 13, 2025

$AKBA
Form 8-K
Filed on: 2025-01-13
Source
Akebia Therapeutics, Inc. 8-K Report: Key Developments on January 13, 2025

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Akebia Therapeutics, Inc.
  • CIK (Central Index Key): 0001517022
  • State: Delaware (DE)
  • SEC File Number: 001-36352
  • EIN (Employer Identification Number): 20-8756903
  • Address: 245 First Street, Cambridge, MA 02142
  • Phone Number: 617-871-2098
  1. Filing Type:
  • Form: 8-K (This form is used to report major events that shareholders should know about.)
  1. Filing Date:
  • Date of Filing: January 13, 2025
  1. Securities Information:
  • Type of Security: Common Stock
  • Par Value: $0.00001 per share
  • Ticker Symbol: AKBA
  • Exchange: NASDAQ
  1. Reporting Period:
  • The reporting period is for a single day, January 13, 2025.

Insights:

  • The filing indicates that Akebia Therapeutics, Inc. has reported a significant event on January 13, 2025, as denoted by the form type (8-K). Stakeholders should review this filing for any material events that may affect the company's operations or stock price.
  • The inclusion of specific identifiers such as the CIK and SEC file number indicates compliance with SEC regulations and enables easier tracking of the company’s filings.
  • The par value of the common stock is very low, which could imply that the company is in a growth phase or has a history of high volatility in its stock price.
  • The company's location in Cambridge, MA, is indicative of a proximity to biotech innovation hubs, which may impact its research and development capabilities.

Overall, this filing serves as a critical communication tool for shareholders and potential investors to keep abreast of important developments at Akebia Therapeutics, Inc.